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Background: Fecal calprotectin (FC) can be a valuable tool to optimize 
health care for patients with inflammatory bowel disease (IBD). The 
objective of this observational study was to determine the level of 
knowledge of the FC test in Mexican patients with IBD. 
Methods: A self-report questionnaire was distributed via Facebook to 
patients with IBD. The survey consisted of 15 questions in two 
categories: the first category assessed knowledge of IBD diagnosis, 
and the second category assessed knowledge of the FC test. 
Results: In total, 460 patients with IBD participated, of which 83.9% 
(386) had ulcerative colitis (UC) and 16.0% (74) had Crohn’s disease 
(CD). Regarding IBD diagnosis, 41.9% of participants stated that they 
did not know of a non-invasive test for fecal matter to identify 
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inflammation of the colon. Regarding the FC test, 57.5% (UC) and 
58.1% (CD) stated that they did not know about the test. Additionally, 
65.8% (UC) and 51.3% (CD) of participants stated that they had never 
received the FC test and 82.6% (UC) and 77.0% (CD) recognized that 
the FC test was difficult to access in their medical practice. 
Furthermore, 66% (UC) and 52.7% (CD) of participants noted that their 
specialist doctor had never suggested the FC test to them, yet 89.1% 
(UC) and 87.8% (CD) stated that they would prefer FC analysis for their 
IBD follow-up assessments. 
Conclusions: There is little knowledge of the FC biomarker among 
Mexican patients with IBD. This suggests the need for greater 
dissemination of its use and scope as a biomarker in IBD.
Keywords 
Inflammatory bowel disease; Fecal calprotectin; Level of knowledge; 
Ulcerative colitis; Crohn’s disease.
de Madrid, Madrid, Spain
Any reports and responses or comments on the 
article can be found at the end of the article.
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Introduction
Inflammatory bowel disease (IBD) is defined as a group of 
chronic inflammatory disorders of unknown cause that affect the 
gastrointestinal tract and includes two diseases: Crohn’s disease 
(CD) and Ulcerative Colitis (UC). These diseases are defined 
according to clinical, radiological, endoscopic, and histologi-
cal criteria, and are characterized by chronic relapses, which 
present in outbreaks (active phases) and periods of remission 
(inactive phases)1.
Currently, gastrointestinal endoscopy, histological examina-
tion of biopsies, and contrast imaging are mandatory techniques 
for the diagnosis and evaluation of IBD activity. Due to the 
complexity of the disease and the need for a multidisciplinary 
approach, diagnosing and treating the condition is a challenge 
for medical specialists. Patients generally take five to ten years 
to be diagnosed, which implies that treatments are applied late 
and therefore, the quality of life of patients with IBD is 
directly affected2. Patients with IBD also worry about a timely 
diagnosis, as well as complications of the disease and secondary 
conditions3,4.
Unfortunately, endoscopy is not easily accessible in many 
rural areas of the Mexican Republic and when performed are 
sometimes unnecessary, a problem compounded by the cost of 
the procedure. Recently, in different international institutions 
the use of biomarkers or biological markers has been routinely 
applied. The most prominent biomarker used for IBD is 
fecal calprotectin (FC), which is a protein derived from 
neutrophils, released in the feces in response to inflammation 
of the intestinal mucosa. FC levels have been found to be asso-
ciated with endoscopic severity, prediction of mucosal healing, 
and prediction of relapse; therefore, it is a useful biomarker 
for monitoring patient response to treatment5,6. Additionally, 
a primary objective of the treatment of IBD is to improve the 
patient’s health-related quality of life regardless of the type of 
therapy used. Patient knowledge of alternative methods for 
diagnosis and follow-up of IBD leads to increased well-
being of the patients and to a reduction in overall healthcare 
costs7.
Despite the clinical utility of FC in IBD, the lack of dissemina-
tion and knowledge among patients could limit its acceptance 
and use as a clinical test. Currently in Mexico, there are no 
official statistics on the use of FC as a diagnostic marker and 
follow-up test for IBD. Consequently, the present study aims 
to assess knowledge regarding the use of FC as a diagnostic 
test among patients with IBD.
Methods
Study design
This study used an observational cross-sectional design. 
Through the “Fundación Vivir con Crohn y CUCI A.C” (a 
non-profit foundation that offers information and support 
to people with IBD in Mexico), an electronic questionnaire 
was disseminated with questions aimed at assessing par-
ticipant knowledge of FC and its use in IBD treatment. The 
questionnaire was developed by “Fundación Vivir con Crohn 
y CUCI A.C”, gastroenterologists and health advocates of 
Hospital C.M.N. “20 de Noviembre”, ISSSTE, in 2020. Two 
gastroenterologists in the group validated the 15 questions. 
A pilot test of the questionnaire was carried out with 5% of the 
population (23 people with IBD who attended the hospital), 
to ensure the validity of the questionnaire. The questionnaire 
was anonymous and voluntary, and consisted of 15 basic ques-
tions about the patient’s social and demographic data, as well as 
questions related to knowledge of the FC test8. A link to the 
questionnaire was posted on the “Fundación Vivir con Crohn y 
CUCI A.C”’s Facebook site on the 3rd July 2020. The survey 
was hosted on Google Forms. 
Participants
Inclusion criteria were Mexican adults, aged 18 to 45 years old 
and diagnosed with inflammatory bowel disease. The sample 
size was calculated using the central limit theorem9 with a 
margin of error of 5% and a confidence interval of 95%. 
According to a previous study by Yamamoto et al., 2015, the 
prevalence of IBD in Mexico is 150,000, and considering an 
expected prevalence difference and an acceptable error of 
5%, the following calculations were made9,10:
 










      Amendments from Version 1
The changes made were in the area of methods, highlighting 
the following: According to a previous study by Yamamoto 
et al., 2015, the prevalence of IBD in Mexico is 150,000, 
and considering an expected prevalence difference and an 
acceptable error of 5 %, the sample size calculations were 
performed, this in order to clarify how the sample size calculation 
was performed. On the other hand, in the area of discussion, 
the reason why there were more cases of Ulcerative Colitis 
and why there was greater participation of women was added, 
adding that even in Mexico it is still a challenge to understand 
the real number of cases of IBD. The predominance of women, 
this imbalance may be due to environmental factors such as 
the use of oral contraceptives, psychosocial stress, dietary 
factors, among others. It was also added that the information 
on this Calprotectin test cannot be omitted, since national and 
international clinical guidelines for the diagnosis and treatment 
of IBD in the adult population recommend the use of the fecal 
calprotectin test in various clinical settings, including initial 
diagnosis, diagnosis of relapse, and response to treatment. 
And finally, internet access was added as a limitation, since it 
could have had an impact on the number of participants who 
answered the questionnaire. Everything added was justified with 
different bibliographic references.
Any further responses from the reviewers can be found at 
the end of the article
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N = Sample size calculation; Zα / 2 = Z value of the alpha error 
with 95% confidence, assigning alpha = 0.05; P = expected 
population prevalence for the event under study (Yamamoto 
et al., 2015); d = Difference between the expected population 
prevalence value and the acceptable error. Values: Zα / 2 = 1.96; 
p = 0.38; d = 0.30.
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Which means that if you survey 384 people, the actual data 
you are looking for will be 95% of the time in the ± 5% range 
relative to the data you see in the survey.
Data collection
A database was produced with Excel v19.0. The period of data 
collection was August to September 2020, where the following 
data were collected from each patient: 1) Type of IBD (UC and 
CD), 2) Sex of the patient, 3) Health System where they were 
treated, 4) Are you familiar with the non-invasive stool test 
to see if the intestine is inflamed? 5) Do you know of any test 
to determine if the disease is in the active phase? 6) Do you 
know of any test to determine if the disease is in the remission 
phase? 7) Do you consider that colonoscopy is necessary for 
the follow-up of IBD? 8) Do you know the FC test? 9) Have 
you ever had the FC test? 10) Does your medical unit have the 
FC test? 11) How accessible is it to perform the FC test in your 
medical unit? 12) How often does the specialist doctor suggest 
that you take the FC test? 13) Do you know approximately 
the cost of the FC test? 14) Do you think the price of the FC 
test is lower than the endoscopy study?, 15) For the follow-up 
of the disease would you prefer to perform Colonoscopy or the 
FC test?
Statistical analysis
Initially, a univariate analysis was carried out, where absolute 
and relative frequencies were used for qualitative variables 
and mean and standard deviation were used for quantitative 
variables. All tests were performed with Excel v19.0.
Ethical considerations
This study was based on the guidelines for clinical research 
established in the Declaration of Helsinki, in the Ministry of 
Health, and in the “Centro Médico Nacional, 20 de Noviembre, 
ISSSTE”. The Institutional Biosafety, Ethics and Research 
Committee, approved this study (number 033.2017). Written 
informed consent was obtained from each patient. As well as in 
the Biosafety, Ethics and Institutional Research Committees, 
patient information was deidentified and data were stored in a 




In total, 460 patients with a diagnosis of IBD were obtained 
in 29 states of the Mexican Republic11. The following states 
and cities of the Mexican Republic were the ones that 
provided the information: Mexico City, Mexico City (131); 
State of Mexico, Toluca de Lerdo (68); Monterrey, Nuevo Leon 
(36); Guadalajara, Jalisco (32); Coahuila, Saltillo (20); Leon, 
Guanajuato (16); Sinaloa, Culiacán (16); Puebla, Puebla (15); 
Morelos, Cuernavaca (12); Veracruz, Xalapa (12); Baja California, 
Mexicali (11); Chihuahua, Chihuahua (11); Pachuca, Hidalgo 
(9); Querétaro, Querétaro (8); Ciudad Victoria, Tamaulipas (8); 
Hermosillo, Sonora (7); Durango, Durango (6); Chilpancingo, 
Guerrero (5); Nayarit, Tepic (5); Oaxaca, Oaxaca (5); Quintana 
Roo, Chetumal (5); San Luis Potosí, San Luis Potosí (5); Tlaxcala, 
Tlaxcala (5); Yucatán, Mérida (3); Aguascalientes, Aguas-
calientes (2); Campeche, Campeche (2); Michoacán, Morelia (2); 
Zacatecas, Zacatecas (2); Tabasco, Villahermosa (1) (Figure 1).
Table 1 shows the general characteristics of the study partici-
pants. Of the 460 patients who participated in the questionnaire, 
there was a greater number of patients with a diagnosis of ulcer-
ative colitis (386; 83.9%) than Crohn’s disease (74, 16.0%), 
and a predominance of women (327, 71%) over men (133, 
28.9%), as well as greater medical attention in the public health 
sector.
Participant knowledge of IBD tests
It was observed that more than 50% of participants were not 
aware of any non-invasive stool test (i.e. not endoscopy) to 
test whether the intestine is inflamed. Additionally, more than 
50% stated that they did not know of any test to differentiate 
whether the disease is in the active or remission phase. 
Moreover, 90% of participants stated that colonoscopy was 
necessary for the follow-up of IBD (Table 2).
Participant knowledge of the fecal calprotectin test
It was observed that more than 50% of participants had no 
knowledge of the FC test and have never had it. Furthermore, 
64% of participants did not know if their medical unit has the 
FC test and 83% consider the test hard to access in their medi-
cal unit. Additionally, more than 65% of the participants stated 
that they had never been offered the FC test. Despite this, 
almost 90% of patients said they would prefer to use the FC 
test to monitor their condition (Table 3).
Discussion
To ensure high quality care for patients with a chronic 
disease, it is important for the patient to have adequate informa-
tion on their diagnosis, treatment and follow-up, and for the 
doctor to inform and discuss different options with the patient. 
Determining patient knowledge of their disease can help 
reduce costs in the health sector and at the same time improve 
the quality of life of patients. Assessing knowledge of fecal 
calprotectin (CF) in patients with IBD is, therefore, important 
to improve patient care for this chronic disease. This study is 
the first to our knowledge to evaluate this in Mexico.
Participants were recruited through the “Fundación Vivir con 
CU y Crohn SA”, and 460 patients with a diagnosis of IBD were 
surveyed, of which, 83.9% were diagnosed with UC and 16.0% 
with CD. The predominance of UC over CD is similar to 
that reported in other countries in Asia and Latin American 
Page 4 of 17
F1000Research 2021, 9:1496 Last updated: 12 FEB 2021
countries, such as Colombia7,11. Although the trend of IBD is 
similar to that of other countries, the lack of epidemiological data 
in Mexico remains a challenge to understand the real number 
of IBD cases. The predominance of women (327, 71%) over 
men (133, 28.9%), this imbalance may be due to environmental 
factors such as the use of oral contraceptives, psychosocial stress, 
dietary factors, among others. On the other hand, it has been 
described that the use of social networks is more frequent in 
women than in men, so it can also be attributed that there is a 
greater number of women12-16.
Figure 1. States of the Mexican Republic from which participants took part. The colours represent the number of participants 
recruited in each state. Mexico City and the State of Mexico (dark red) presented the greatest number of participants (over 40) with IBD. 
Monterrey and Guadalajara (red) presented 21 to 40 participants with IBD. The states of Coahuila, León and Sinaloa (orange) presented 21 
to 40 participants with IBD. Puebla, Morelos, Veracruz, Baja Calicfornia and Chihuahua (yellow) presented 11 to 15 participants with IBD. 
Pachuca, Querétaro, Ciudad Victoria, Hermosillo and Durango (dark green) presented 6 to 10 participants with IBD. Chilpancingo, Nayarit, 
Oaxaca, Quintana Roo, San Luis Potosí, Tlaxacala, Yucatán, Aguascalientes, Campeche, Michoacán, Zacatecas and Tabasco (light green) 
presented 1 to 5 participants with IBD.
Table 1. General characteristics of the study population.
Ulcerative Colitis (UC) Crohn’s disease (CD)
Number of participants (%) 83.9 % (386) 16.0 % (74)








Data are presented as number (%), and median/±
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In the first category of questioning about the participants’ 
knowledge of IBD tests, participants mostly reported to not 
know of any test for the state of the disease. This shows that the 
majority of participants were uninformed, which can lead to 
a deterioration in the quality of life17. When living with a 
chronic disease, it is essential to know about advances in medi-
cine, to know the signs and symptoms, and how to better 
diagnose and monitor the disease to improve quality of life. 
The benefits of staying properly informed include awareness of 
useful tools and tests to diagnose and prevent the advancement 
of the disease11,18,19.
More than 90% of the participants stated that colonoscopy is 
necessary for the follow-up of IBD. Colonoscopy can be 
used in the initial differential diagnosis, in the surveillance of 
carcinoma, and to evaluate abnormalities on imaging tests. 
However, undergoing a colonoscopy is invasive, expensive, and 
intolerable for some patients. In other studies, patients have 
claimed to have anxiety before and during the colonoscopy, 
given potential risks such as intestinal perforation. Colonoscopy 
has also been associated with several unfavorable outcomes, 
including missed diagnoses and avoidable repeat procedures20,21. 
In addition, it is difficult to perform an endoscopic evaluation 
when there is injury to the intestinal mucosa, a frequent problem 
in IBD22–24.
In the second part of the questionnaire to identify the degree of 
knowledge of the CF test, more than 50% of the population 
in both groups answered that they had no knowledge of the FC 
test. They also said that the FC test had never been performed 
on them, and that their specialist doctor had never suggested 
performing the FC test. This highlights the scarcity of knowl-
edge regarding this test in treating patients with IBD, and that 
the doctor-patient relationship seems deficient. The doctor must 
inform the patient of their pathology, the procedures to follow, 
the treatment possibilities, eventual healing and, in general, must 
adhere to correct clinical practice to improve the information 
perceived by patients25,26.
In addition, it must be clear that the only effective informa-
tion is that provided by the health professional before the inter-
vention or treatment in question. Adequate information should 
be provided sufficiently in advance and be honest and easy 
to understand, so that the patient can make an informed 
decision27. That is why the dissemination of information to 
the patient, including the benefits and disadvantages of any 
potential procedure should be made known28.
The study participants were questioned about the accessibil-
ity of the FC test in their medical unit. More than 70% stated 
that it was difficult to access this test, and in contrast, more 
than 50% of the population reported not knowing whether this 
test is available in their medical unit. The Mexican Consen-
sus for the diagnosis and treatment of IBD suggests that the 
FC test is useful to evaluate the activity of IBD. The test’s 
response to medical treatment correlates with mucosal scarring 
or endoscopic remission, and is a good predictor of relapse, so 
access should be easily available in any medical unit29. Further-
more, expert guidelines suggest that disease activity should be 
reassessed every 3 to 6 months30, therefore, it would be impor-
tant for public and private medical units to have the FC test 
for regular cost-effective testing22,31.
In questions about the cost of FC, more than 60% of partici-
pants stated that they did not know the cost of the test, and 
more than 60% believed that the price of FC is less than a 
Table 2. Participant knowledge of IBD tests.
Ulcerative Colitis (UC) 
n= 386 (83.9 %)
Crohn’s disease (CD) 
n= 74 (16 %)
Are you familiar with the non-invasive stool 
test to see if the intestine is inflamed? 
                                   Yes 
                                   No
 
 




32 (43.2 %) 
42 (56.7 %)
Do you know of any tests to know if it is in 
the active phase? 
                                   Yes 
                                   No
 
142 (36.7 %) 
244 (63.2 %)
 
32 (43.2 %) 
42 (56.7 %)
Do you know of any test to know if it is in 
the remission phase? 
                                   Yes 
                                   No
 
120 (31.0 %) 
266 (68.9 %)
 
32 (43.2 %) 
42 (56.7 %)
Do you consider that colonoscopy is 
necessary for the follow-up of IBD? 
                                   Yes 
                                   No
 
352 (91.1 %) 
34 (8.8 %)
 
67 (90.5 %) 
7 (9.4 %)
Data are presented as number (%)
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colonoscopy. On the contrary, a study carried out by 
Motaganahalli et al., in 2019, suggests that the introduction of 
the FC test in the routine health care of IBD not only helps the 
patient, but is potentially cheaper than a colonoscopy32. The 
use of colonoscopies could be reduced by more than 80% if the 
FC test is used as the first approach33. In addition, the use of 
the FC test over a colonoscopy would be more profitable, 
indirectly, for the patient, since colonoscopies cause loss of 
productivity and absence from work, require sedation and 
attendance at a medical care center34,35.
Finally, the participants were questioned about which test 
they would prefer to carry out for an IBD follow-up appoint-
ment. More than 80% stated that they would prefer the FC 
test. FC could not only be useful in the differentiation of 
patients with active IBD and those in remission, but it also cor-
relates well with the degree of inflammatory activity evalu-
ated by clinical indices such as endoscopy and histology, and 
predicts clinical relapse, as well as the mucosal healing and 
postoperative recurrence36,37. Other authors have shown that FC 
levels are associated with the presence of histological alterations 
in endoscopic biopsies, being lower in the absence of anato-
mopathological inflammation38–40. In different cohorts it has also 
been reported that the FC test is able to distinguish IBD from 
Irritable Bowel Syndrome41,42. Therefore, the use of an alter-
native non-invasive biomarker such as FC that can accurately 
differentiate functional or organic diseases, detect inflamma-
tion of the intestinal mucosa, and monitor disease activity to 
Table 3. Participant knowledge of the non-invasive Fecal Calprotectin test.
Ulcerative Colitis (UC) 
n= 386 (83.9 %)
Crohn’s disease (CD) 
n= 74 (16 %)
Are you familiar with the test called Fecal Calprotectin? 
                                            Yes 
                                            No
 
164 (42.4 %) 
222 (57.5 %)
 
31 (41.8 %) 
43 (58.1 %)
Have you ever had a Fecal Calprotectin test? 
                                            Yes 
                                            No
 
132 (34.1 %) 
254 (65.8 %)
 
36 (48.6 %) 
38 (51.3 %)
How often does the specialist doctor suggests 
performing the FC test? 
                                  Every 3–4 months 
                                   Every 6 months 
                                      Once a year 
         One time only to prescribe another medicine 
                                           Never
 
35 (9.0 %) 
39 (10.1 %) 
27 (6.9 %) 
30 (7.7 %) 
255 (66.0 %)
 
6 (8.1 %) 
9 (12.1 %) 
8 (10.8 %) 
12 (16.2 %) 
39 (52.7 %)
Does your medical unit have the FC test? 
                                            Yes 
                                            No 
                                     I don’t know
 
65 (16.8 %) 
74 (19.1 %) 
247 (63.9 %)
 
17 (22.9 %) 
19 (25.6 %) 
38 (51.3 %)
How accessible is it to take the FC test in your medical 
unit? 
                                          Hard 
                                          Easy
 
319 (82.6 %) 
67 (17.3 %)
 
57 (77.0 %) 
17 (22.9 %)
Do you know the approximate cost of the FC test? 
                                            Yes 
                                            No
 
103 (26.6 %) 
283 (73.3 %)
 
23 (31.0 %) 
51 (68.9 %)
Do you think the price of the FC test is less than the 
endoscopy study? 
                                            Yes 
                                            No
 
274 (70.9 %) 
112 (29.01 %)
 
51 (68.9 %) 
23 (31.0 %)
For the follow-up of the disease you prefer to perform: 
                                    Colonoscopy  
                                Fecal Calprotectin
 
42 (10.8 %) 
344 (89.1 %)
 
9 (12.1 %) 
65 (87.8 %)
Data are presented as number (%)
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avoid invasive and costly testing could be highly useful43,44. 
Likewise, this information cannot necessarily be omitted, since 
clinical guidelines such as that of European Crohn’s and Colitis 
Organization [ECCO] the European Society of Gastrointestinal, 
Abdominal Radiology [ESGAR], British Society of Gastroen-
terology consensus guidelines and Mexican guidelines for the 
Diagnosis and Treatment of IBD in the Adult Population, rec-
ommend the use of the fecal calprotectin test in various clini-
cal settings, including initial diagnosis, relapse diagnosis and 
response to treatment45-48.
Assessing patient knowledge of non-invasive tests such as 
FC in patients with IBD may help to improve patient care as 
well as a reduction in medical costs during follow-up of the 
disease. This study suggests that knowledge of such tests can 
be improved with better communication with the medical 
personnel. The limitations of the study were that there was 
a much greater number of participants with ulcerative coli-
tis than Crohn’s disease, and the patients were only evaluated 
cross-sectionally. On the other hand, there is growing evidence 
suggesting that Facebook is a useful recruiting tool and there-
fore its use should be considered when implementing future 
health research. However, one of the important limitations 
of this study is Internet access.
In general, patients with chronic diseases should know about 
the tests that help to diagnose and monitor their disease. 
For IBD, assessing a biological biomarker, such as FC, is more 
specific than clinical indices, less expensive, more comfortable 
than endoscopic monitoring, and reduces the need for endo-
scopic examinations. Therefore, patients with IBD should be 
given the correct information on the use of FC which could be a 
valid alternative to evaluate the response to treatment and 
reduce the number of colonoscopies performed. To improve 
knowledge transfer to patients, we suggest improving acces-
sibility to services, creating comprehensive care units, having 
medical specialists inform their patients about management 
of the disease, promoting medical research on the disease, and 
likewise, raising more awareness in society about IBD.
Conclusion
Using the application of a questionnaire, we evaluated the 
knowledge of patients with IBD about the diagnostic tests 
that are required for the diagnosis and follow-up of the dis-
ease. There was a lack of awareness of the effective and 
low-cost  Fecal Calprotectin test in the participants. In order 
for patients to make informed decisions regarding the man-
agement of their disease, doctors should provide ade-




Harvard Dataverse: Patient knowledge of fecal calprotectin in 
inflammatory bowel disease (IBD): An observational study in 
Mexico. https://doi.org/10.7910/DVN/AHPJOF11 
This project contains the following underlying data:
-      Database Maldonado et al.tab. (Excel spreadsheet of 
questionnaire responses)
Extended data
Harvard Dataverse: Patient knowledge of fecal calprotectin in 
inflammatory bowel disease (IBD): An observational study in 
Mexico. https://doi.org/10.7910/DVN/NOOUQF8 
This project contains the following extended data:
-      Questionnaire in English
-      Questionnaire in Spanish
Data are available under the terms of the Creative Commons 
Attribution 4.0 International license (CC-BY 4.0).
Consent
Written informed consent for publication of the participants’ 
details was obtained from participants.
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It seems that the questionnaire had been previously used in another study (as a reference is 
provided for it). Was it previously validated? Please clarify this. 
 
As the questionnaire was posted on Facebook site, there may be a bias for including only patients 
with internet access (which could be associated, for example, with younger age, higher 
educational status, etc.). This potential limitation should be discussed in the Discussion section. 
 
In this respect, inclusion criteria were Mexican adults, aged 18 to 45 years old. Please justify this. 
This could induce another bias, as older patients could have lower internet access. Therefore, the 
results of the present study could have been biased to more favorable findings. This potential 
limitation should also be discussed in the Discussion section. 
 
It is stated that the sample size was calculated using the central limit theorem with a margin of 
error of 5% and a confidence interval of 95%. However, more details should be provided, and the 
calculated sample size should be given. 
 
Statistical analysis: It is stated that “Initially, a univariate analysis was carried out”. This seems to 






Of the 460 patients who participated in the questionnaire, there was a much greater number of 
patients with a diagnosis of ulcerative colitis (386; 83.9%) than Crohn’s disease (74, 16.0%). Even 
though the authors point out that “The predominance of UC over CD is similar to that reported in 
other countries in Asia and Latin American countries, such as Colombia”, and they comment in the 
Discussion section that “The limitations of the study were that there was a much greater number 
of participants with ulcerative colitis than Crohn’s disease”, these explanations seem to be 
insufficient. Please try to explain better this possible bias. 
 
The same is valid for the predominance of women (327, 71%) over men (133, 28.9%), please try to 
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It is repeatedly stated that: “The majority of participants were uninformed, which can lead to a 
deterioration in the quality of life”. And that “They also said that the FC test had never been 
performed on them and that their specialist doctor had never suggested performing the FC test. 
This highlights the scarcity of knowledge regarding this test in treating patients with IBD, and that 
the doctor-patient relationship seems deficient”. However, it should also be clarified that the lack 
of knowledge of the patient does not necessarily imply that the doctor has not informed the 
patient correctly, since it is possible that the determination of FC is simply not indicated in them. In 
other words, it is clear that FC is not always indicated in all patients, and for those patients, this 
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Reviewer 1: It seems that the questionnaire had been previously used in another study (as a 
reference is provided for it). Was it previously validated? Please clarify this. 
 
Answer: Thanks for the comment. The questionnaire was developed by “Fundación Vivir con 
Crohn y CUCI A.C”, gastroenterologists and health advocates of Hospital C.M.N. "20 de 
Noviembre", ISSSTE, in 2020. It is an original questionnaire, without prior use. Two 
gastroenterologists in the group validated the 15 questions. A pilot test of the questionnaire was 
carried out with 5% of the population (23 people with IBD who attended the hospital), to ensure 
the validity of the questionnaire. 
 
Reviewer 1: As the questionnaire was posted on Facebook site, there may be a bias for 
including only patients with internet access (which could be associated, for example, with 
younger age, higher educational status, etc.). This potential limitation should be discussed 
in the Discussion section. 
 
Answer: Thank you for the suggestion. It will be added as a limitation in the discussion. 
……Although there is growing evidence to suggest that Facebook is a useful recruiting tool and 
therefore its use should be considered when implementing future health research. However, one 
of the important limitations of this study is Internet access…. 
Whitaker, C., Stevelink, S., & Fear, N. (2017). The Use of Facebook in Recruiting Participants for 
Health Research Purposes: A Systematic Review. Journal of medical Internet research, 19(8), e290. 
https://doi.org/10.2196/jmir.7071 
 
Reviewer 1: In this respect, inclusion criteria were Mexican adults, aged 18 to 45 years old. 
Please justify this. This could induce another bias, as older patients could have lower 
internet access. Therefore, the results of the present study could have been biased to more 
favorable findings. This potential limitation should also be discussed in the Discussion 
section. 
 
Answer: Thanks for the suggestion. The inclusion criterion based on the age of 18 to 45 years of 
age, was chosen because in previous studies it is presented primarily to people of productive age 
(Sairenji, T., Collins, K. L., & Evans, D. V. (2017). An Update on Inflammatory Bowel 
Disease. Primary care, 44(4), 673–692. https://doi.org/10.1016/j.pop.2017.07.010. Kamp, K., 
Dudley-Brown, S., Heitkemper, M., Wyatt, G., & Given, B. (2020). Symptoms among emerging 
adults with inflammatory bowel disease: a descriptive study. Research in nursing & health, 43(1), 
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48–55. https://doi.org/10.1002/nur.21985) 
 
Reviewer 1: It is stated that the sample size was calculated using the central limit theorem 
with a margin of error of 5% and a confidence interval of 95%. However, more details 
should be provided, and the calculated sample size should be given. 
 
Answer: According to a previous study by Yamamoto et al., 2015, the prevalence of IBD in Mexico 
is 150,000, and considering an expected prevalence difference and an acceptable error of 5%, the 
following calculations were made: 
N=Zα22p1-pd2 
N = Sample size calculation; Zα / 2 = Z value of the alpha error with 95% confidence, assigning 
alpha = 0.05; P = expected population prevalence for the event under study (Yamamoto et al., 
2015); d = Difference between the expected population prevalence value and the acceptable error. 
Values: Zα / 2 = 1.96; p = 0.38; d = 0.30. 
N= 1.9620.381-0.380.302= 384 
 
This means that if you survey 384 people, the actual data you are looking for will be 95% of the 
time in the ± 5% range relative to the data you see in the survey. 
 
Reviewer 1: Statistical analysis: It is stated that “Initially, a univariate analysis was carried 
out”. This seems to imply that a multivariate analysis was also performed, but I cannot see 
any information regarding it. 
 




Of the 460 patients who participated in the questionnaire, there was a much greater 
number of patients with a diagnosis of ulcerative colitis (386; 83.9%) than Crohn’s disease 
(74, 16.0%). Even though the authors point out that “The predominance of UC over CD is 
similar to that reported in other countries in Asia and Latin American countries, such as 
Colombia”, and they comment in the Discussion section that “The limitations of the study 
were that there was a much greater number of participants with ulcerative colitis than 
Crohn’s disease”, these explanations seem to be insufficient. Please try to explain better this 
possible bias. 
 
Answer: Thanks for the suggestion. We add the explanation 
 
“The limitations of the study were that there was a much greater number of participants 
with ulcerative colitis than Crohn’s disease”. Although the trend of IBD is similar to other 
countries, the lack of epidemiological data in Mexico is still a challenge to understand the 
true number of IBD cases. 
 
Yamamoto-Furusho, J. K., Bosques-Padilla, F. J., Charúa-Guindic, L., Cortés-Espinosa, T., 
Miranda-Cordero, R. M., Saez, A., & Ledesma-Osorio, Y. (2020). Inflammatory bowel disease 
in Mexico: Epidemiology, burden of disease, and treatment trends. Epidemiología, carga de 
la enfermedad y tendencias de tratamiento de la enfermedad inflamatoria intestinal en 
 
Page 14 of 17
F1000Research 2021, 9:1496 Last updated: 12 FEB 2021
México. Revista de gastroenterologia de Mexico, 85(3), 246–256. 
https://doi.org/10.1016/j.rgmx.2019.07.008 
 
The same is valid for the predominance of women (327, 71%) over men (133, 28.9%), please 
try to explain this misbalance. 
 
Answer: Thanks for the suggestion. We add the explanation 
 
The predominance of women (327, 71%) over men (133, 28.9%), this imbalance may be due 
to environmental factors such as the use of oral contraceptives, psychosocial stress, dietary 
factors, among others. On the other hand, it has been described that the use of social 
networks is more frequent in women than in men, so it can also be attributed that there is a 
greater number of women. 
 
Grosberg, D., Grinvald, H., Reuveni, H., & Magnezi, R. (2016). Frequent Surfing on Social 
Health Networks is Associated With Increased Knowledge and Patient Health Activation. 
Journal of medical Internet research, 18(8), e212. https://doi.org/10.2196/jmir.5832 
Algethmi, W., Baumann, C., Alnajjar, W., Sroji, A., Alsahafi, M., Jawa, H., Qari, Y., Peyrin-
Biroulet, L., Saadah, O. I., & Mosli, M. (2020). Environmental exposures and the risk of 
inflammatory bowel disease: a case-control study from Saudi Arabia. European journal of 
gastroenterology & hepatology, 32(3), 358–364. 
https://doi.org/10.1097/MEG.0000000000001619 
Wang, X., Fan, X., Deng, H., Zhang, X., Zhang, K., Xu, J., Li, N., Han, Q., & Liu, Z. (2019). Use of 
oral contraceptives and risk of ulcerative colitis - A systematic review and meta-analysis. 
Pharmacological research, 139, 367–374. https://doi.org/10.1016/j.phrs.2018.11.036 
Ho, S. M., Lewis, J. D., Mayer, E. A., Plevy, S. E., Chuang, E., Rappaport, S. M., Croitoru, K., 
Korzenik, J. R., Krischer, J., Hyams, J. S., Judson, R., Kellis, M., Jerrett, M., Miller, G. W., Grant, 
M. L., Shtraizent, N., Honig, G., Hurtado-Lorenzo, A., & Wu, G. D. (2019). Challenges in IBD 





It is repeatedly stated that: “The majority of participants were uninformed, which can lead 
to a deterioration in the quality of life”. And that “They also said that the FC test had never 
been performed on them and that their specialist doctor had never suggested performing 
the FC test. This highlights the scarcity of knowledge regarding this test in treating patients 
with IBD, and that the doctor-patient relationship seems deficient”. However, it should also 
be clarified that the lack of knowledge of the patient does not necessarily imply that the 
doctor has not informed the patient correctly, since it is possible that the determination of 
FC is simply not indicated in them. In other words, it is clear that FC is not always indicated 
in all patients, and for those patients, this information could be correctly omitted. Please 
clarify this in the Discussion section. 
 
Answer: Thanks for the comment. We add the explanation. 
 
This information cannot necessarily be omitted, since clinical guidelines such as that of 
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European Crohn’s and Colitis Organization [ECCO] the European Society of Gastrointestinal, 
Abdominal Radiology [ESGAR], British Society of Gastroenterology consensus guidelines and 
Mexican guidelines for the Diagnosis and Treatment of IBD in the Adult Population, 
recommend the use of the fecal calprotectin test in various clinical settings, including initial 
diagnosis, relapse diagnosis and response to treatment. 
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